Association of Socioeconomic Status With Risk Factor Target Achievements and Use of Secondary Prevention After Myocardial Infarction.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
entrez:
10
3
2021
pubmed:
11
3
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Low socioeconomic status (SES) is associated with poor long-term prognosis after myocardial infarction (MI). Plausible underlying mechanisms have received limited study. To assess whether SES is associated with risk factor target achievements or with risk-modifying activities, including cardiac rehabilitation programs, monitoring, and drug therapies, during the first year after MI. This cohort study included a population-based consecutive sample of 30 191 one-year survivors of first-ever MI who were 18 to 76 years of age, resided in the general community in Sweden, were followed up until their routine 11- to 15-month revisit, and were registered in the national registry Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) from 2006 through 2013. Data analyses were performed from January to August 2020. Individual-level SES by proxy disposable income quintile. Secondary exposures were educational level and marital status. Odds ratios (ORs) with 95% CIs for achieved risk factor targets at the 1-year revisit and for use of guideline-recommended secondary prevention activities. The study comprised 30 191 participants (72.9% men) with a mean (SD) age of 63.0 (8.6) years. Overall, higher SES was associated with better target achievements and use of most secondary prevention. The highest (vs lowest) income quintile was associated with achieved smoking cessation (OR, 2.05; 95% CI, 1.78-2.35), target blood pressure levels (OR, 1.17; 95% CI, 1.07-1.27), and glycated hemoglobin levels (OR, 1.57; 95% CI, 1.19-2.06). The highest-income quintile was associated not only with participation in physical training programs (OR, 2.28; 95% CI, 2.11-2.46) and patient educational sessions (OR, 2.29; 95% CI, 2.12-2.47) in cardiac rehabilitation but also with more monitoring of lipid profiles (OR, 1.20; 95% CI, 1.08-1.33) and intensification of statin therapy (OR, 1.22; 95% CI, 1.11-1.35) during the first year after MI. One year after MI, the highest-income quintile was associated with persistent use of statins (OR, 1.26; 95% CI, 1.10-1.45), high-intensity statins (OR, 1.10; 95% CI, 1.00-1.21), and renin-angiotensin-aldosterone system inhibitors (OR, 1.27; 95% CI, 1.08-1.49). Findings indicated that, in a publicly financed health care system, higher SES was associated with better achievement of most risk factor targets, programs aimed at lifestyle change, and evidence-based drug therapies after MI. Observed differences in secondary prevention activity may be a factor in higher long-term risk of recurrent disease among individuals with low SES.
Identifiants
pubmed: 33688966
pii: 2777316
doi: 10.1001/jamanetworkopen.2021.1129
pmc: PMC7948055
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e211129Références
BMC Sports Sci Med Rehabil. 2019 Jul 26;11:13
pubmed: 31372231
Eur J Prev Cardiol. 2019 May;26(8):824-835
pubmed: 30739508
BMC Cardiovasc Disord. 2016 May 31;16:115
pubmed: 27246583
Eur Heart J. 2020 May 1;41(17):1653-1661
pubmed: 31638654
Am Heart J. 2011 Oct;162(4):571-584.e2
pubmed: 21982647
Eur J Prev Cardiol. 2019 Nov;26(17):1816-1823
pubmed: 31067128
Eur J Prev Cardiol. 2016 Apr;23(6):636-48
pubmed: 25687109
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Am Heart J. 2006 Jun;151(6):1205-13
pubmed: 16781220
Cochrane Database Syst Rev. 2017 Jun 28;6:CD008895
pubmed: 28658719
Eur J Prev Cardiol. 2020 Jan;27(2):145-154
pubmed: 31514507
J Am Heart Assoc. 2020 Mar 3;9(5):e015491
pubmed: 32114890
Psychosom Med. 2018 Oct;80(8):742-753
pubmed: 30281027
Atherosclerosis. 2016 Sep;252:207-274
pubmed: 27664503
Can J Cardiol. 2013 Dec;29(12):1599-603
pubmed: 24404611
Dan Med J. 2013 Mar;60(3):A4591
pubmed: 23484610
JAMA. 2003 Jul 2;290(1):86-97
pubmed: 12837716
Circulation. 2011 Nov 29;124(22):2458-73
pubmed: 22052934
Int J Cardiol. 2016 Sep 15;219:70-8
pubmed: 27288969
Eur J Epidemiol. 2009;24(11):659-67
pubmed: 19504049
Heart. 2015 May 15;101(10):800-7
pubmed: 25801001
Eur J Prev Cardiol. 2016 Dec;23(18):1994-2006
pubmed: 27600690
Eur J Prev Cardiol. 2016 May;23(8):881-90
pubmed: 26283652
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2960-84
pubmed: 24239922
Heart. 2010 Oct;96(20):1617-21
pubmed: 20801780
Circulation. 2015 Sep 1;132(9):873-98
pubmed: 26240271
Cochrane Database Syst Rev. 2016 Jan 05;(1):CD001800
pubmed: 26730878
Eur J Prev Cardiol. 2018 Jun;25(9):985-993
pubmed: 29664673
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Eur J Prev Cardiol. 2020 Mar;27(5):478-489
pubmed: 31597473
PLoS One. 2014 Jan 08;9(1):e83705
pubmed: 24416171
Circulation. 2018 May 15;137(20):2166-2178
pubmed: 29760227
Eur J Prev Cardiol. 2020 Dec;27(18):1944-1952
pubmed: 31958380
Int J Cardiol Hypertens. 2020 Dec 20;8:100074
pubmed: 33884367
Eur J Public Health. 2008 Oct;18(5):479-83
pubmed: 18614608
J Am Coll Cardiol. 2013 Nov 5;62(19):1791-801
pubmed: 23973701
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Eur J Cardiovasc Prev Rehabil. 2011 Jun;18(3):533-41
pubmed: 21450653